A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty

Inclusion Criteria

• Are scheduled for a primary unilateral THA;
• Are able and willing to provide voluntary written informed consent for participation in the study;
• Are between the ages of 18 and 85 at the time of surgery;
• Are willing to comply with all aspects of the treatment and evaluation period

Exclusion Criteria

• Are known to be sensitive to any materials of bovine origin;
• Are undergoing a bilateral or revision THA;
• Patients predonating autologous blood.
• Patients with a preoperative platelet count of less than 100,000.
• Patients with a previous history of venous thromboembolism or deep vein thrombosis
• Medical condition requiring anticoagulation
• Currently using Coumadin
• History of Heparin induced thrombocytopenia or Lovenox induced thrombocytopenia
• Have a history of rheumatoid arthritis or inflammatory arthritis;
• Peripheral vascular disease.
• Evidence of bleeding or metabolic - based hemolytic disorder (hemophilia or anticoagulation use), or hypercoaguable disorder.
• Patients with history of liver disease. Patients with liver dysfunction from cirrhosis or hepatitis may have impaired production of factors in the clotting cascade which may make these individuals more prone to bleed, especially with the use of anticoagulants. For this reason, these patients will also be excluded from this study if a baseline INR is greater than 1.3 or APTT greater than 32.4
• Have a history of failed treatment for abuse of, or are actively abusing, illegal drugs, solvents, or alcohol;
• Have a systemic infection or infection at site of surgery;
• Are a prisoner; and/or
• Are pregnant or nursing.
• Condition deemed by physician or medical staff to be non-conducive to patient's ability to complete the study, or a potential risk to the patient's health and well-being.